Posts under Press

Maze Therapeutics to Participate in Upcoming Investor Conferences

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, CA., February 26, 2024 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that company management will participate in upcoming investor conferences in February and…

Maze Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 09:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D.,…

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease December 14, 2023 08:30 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a…

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease December 11, 2023 04:54 PM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a…

Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Highlights New Preclinical Data Supporting Advancement of APOL1 Inhibitor Candidate Toward Clinical Evaluation for APOL1 Kidney Disease Data Presented During ASN Kidney Week 2023 Demonstrate Significant Reversal of Albuminuria in Chronic Disease Model First-in-Human Trial of MZE829 Development…

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria Findings to be Presented During Poster Session at Kidney Week 2023 SOUTH SAN FRANCISCO, CA., October 13, 2023–Maze Therapeutics, a company…

Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease Findings Published in JASN in Partnership with the Million Veteran Program and Vanderbilt University Medical Center SOUTH…

Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference SOUTH SAN FRANCISCO, CA., September 21, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will participate in a fireside chat…

Live Webcast! June 8, 2023, 11:30am ET

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…

Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Posted by amanda punzalan under Press (No Respond)

Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…